NDATOPICALCREAM
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TOLAK (fluorouracil) by Pfizer is nucleic acid synthesis inhibitors [moa]. Approved for colorectal cancer, gastric cancer, esophageal cancer and 2 more indications. First approved in 2015.
Drug data last refreshed Yesterday
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications (5)
Worked on TOLAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.